Skip to main content
. 2012 Nov 20;108(1):107–114. doi: 10.1038/bjc.2012.517

Figure 1.

Figure 1

Autoantibodies to p53 peptide (microarray) and p53 protein (ELISA) in time of diagnosis set I, time of diagnosis set II, and the UKCTOCS set. DOTPLOT of serum IgG autoantibodies binding to 15-mer scanning p53 peptides measured by peptide-array assay and expressed as relative fluorescence units (RFU) (y-axis). (A) Serum from healthy (n=53) and colorectal cancer individuals (n=58) (time of diagnosis #1). (B) Serum from healthy (n=40) and colorectal cancer individuals (n=157) in time of diagnosis set #2 (training set). (C) Serum from last sample before diagnosis in controls (n=94) and colorectal cancer (n=97) individuals from the UKCTOCS set. Bar graphs represent the sensitivity for each p53 peptide at 95% specificity.